Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study
Year: 2020
Type: article
Study design: Observational Study
Abstract: Epigenetic alterations measured in blood may help guide breast cancer treatment. The multisite prospective study TBCRC 005 was conducted to examine the ability of a novel panel of cell-free DNA methylation markers to predict survival outcomes in metastatic breast cancer (MBC) using a new quantitative multiplex assay (cMethDNA).
DOI: 10.17615/rtxh-x943
Authors: Cope, Leslie M., Nanda, Rita, Lopez-Bujanda, Zoila A., Euhus, David M., Lin, Nancy U., Visvanathan, Kala, Jeter, Stacie C., Sokoll, Lori J., Carey, Lisa A., Storniolo, Anna M., Fackler, Maryjo S., Garrett-Mayer, Elizabeth, Umbricht, Christopher B., Zhang, Zhe, Forero, Andres, Ingle, James N., Wolff, Antonio C., Sukumar, Saraswati
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funders: Array BioPharma, Genentech
OpenAlex ID: W4297960511